[Fundamental study on tissue distribution of ceftriaxone in the field of obstetrics and gynecology]. 1984

O Fukuda, and S Miyamura, and S Inoue, and M Maeyama

Fundamental study on tissue distribution of ceftriaxone (Ro 13-9904, CTRX), a new cephalosporin parenteral antibiotic, was studied and the following results were obtained. CTRX had been administered by intravenous drip infusion with 1 g to 9 cases who received simple total hysterectomy. The level of CTRX in the cubital venous serum and uterine arterial serum was determined as well as the tissue concentration in the oviduct, ovary, endometrium, myometrium, cervix uteri and portio vaginalis. The level in the oviduct and portio vaginalis was generally high, although it was observed only in a few cases. The variation of the level in the myometrium was large. CTRX is expected to be clinically useful considering the fact that its half-life time is 8.5 hours, which is longer than that of existing cephalosporin antibiotics.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D005260 Female Females
D005836 Genitalia, Female The female reproductive organs. The external organs include the VULVA; BARTHOLIN'S GLANDS; and CLITORIS. The internal organs include the VAGINA; UTERUS; OVARY; and FALLOPIAN TUBES. Accessory Sex Organs, Female,Sex Organs, Accessory, Female,Genital Organs, Female,Genitals, Female,Reproductive System, Female,Female Genital,Female Genital Organ,Female Genital Organs,Female Genitalia,Female Genitals,Female Reproductive System,Female Reproductive Systems,Genital Organ, Female,Genital, Female,Reproductive Systems, Female
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
O Fukuda, and S Miyamura, and S Inoue, and M Maeyama
December 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!